CLGN vs. RBOT, MLSS, LFWD, NTRB, COCH, INGN, CRTX, ENZ, GMTX, and ICCM
Should you be buying CollPlant Biotechnologies stock or one of its competitors? The main competitors of CollPlant Biotechnologies include Vicarious Surgical (RBOT), Milestone Scientific (MLSS), ReWalk Robotics (LFWD), Nutriband (NTRB), Envoy Medical (COCH), Inogen (INGN), Cortexyme (CRTX), Enzo Biochem (ENZ), Gemini Therapeutics (GMTX), and IceCure Medical (ICCM). These companies are all part of the "medical" sector.
Vicarious Surgical (NYSE:RBOT) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability, community ranking and analyst recommendations.
Vicarious Surgical currently has a consensus price target of $0.67, indicating a potential upside of 135.32%. CollPlant Biotechnologies has a consensus price target of $11.00, indicating a potential upside of 103.70%. Given CollPlant Biotechnologies' higher possible upside, equities analysts clearly believe Vicarious Surgical is more favorable than CollPlant Biotechnologies.
Vicarious Surgical has a net margin of 0.00% compared to Vicarious Surgical's net margin of -64.05%. Vicarious Surgical's return on equity of -22.17% beat CollPlant Biotechnologies' return on equity.
In the previous week, Vicarious Surgical had 1 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 2 mentions for Vicarious Surgical and 1 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.20 beat Vicarious Surgical's score of 0.00 indicating that Vicarious Surgical is being referred to more favorably in the media.
CollPlant Biotechnologies received 125 more outperform votes than Vicarious Surgical when rated by MarketBeat users. Likewise, 58.59% of users gave CollPlant Biotechnologies an outperform vote while only 38.10% of users gave Vicarious Surgical an outperform vote.
47.3% of Vicarious Surgical shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 14.7% of Vicarious Surgical shares are owned by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
CollPlant Biotechnologies has higher revenue and earnings than Vicarious Surgical. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.
Vicarious Surgical has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.
Summary
Vicarious Surgical beats CollPlant Biotechnologies on 9 of the 17 factors compared between the two stocks.
Get CollPlant Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CollPlant Biotechnologies Competitors List
Related Companies and Tools
